Immunologic Factor
Royalty Pharma Invests $250M in Biogen’s Late-Stage Lupus Treatment
Biogen, Royalty Pharma, litifilimab, lupus, Phase 3 trials, R&D funding, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)
AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial
Rosnilimab, PD-1 agonist, rheumatoid arthritis, Phase 2b trial, immune modulation, AnaptysBio, autoimmune disease
Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab
Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline
Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure
Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure
Roivant Halts Lung Disease Drug Development as Bio-Thera and Intas Forge Biosimilar Partnership
Roivant Sciences, namilumab, pulmonary sarcoidosis, Bio-Thera Solutions, Intas Pharmaceuticals, golimumab biosimilar, BAT2506, Accord BioPharma
Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial
Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function
Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer
personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial
AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset
AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry
FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment
Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement
RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses
Robert F. Kennedy Jr., HHS Secretary nomination, vaccine misinformation, autism, Senate confirmation hearings, written responses